Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferons and Behçet's disease].

B Wechsler1, L T H Du-Boutin

  • 1Service de médecine interne, CHU Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, Paris, France. bertrand.wechsler@psl.ap-hp-paris.fr

La Revue De Medecine Interne
|December 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of virtual fencing in a mountain environment and its impact on heifer behaviour and welfare.

Animal : an international journal of animal bioscience·2025
Same author

Risk factors for tail lesions in undocked fattening pigs reared on Swiss farms.

Schweizer Archiv fur Tierheilkunde·2020
Same author

Body size in relation to cubicle dimensions affects lying behavior and joint lesions in dairy cows.

Journal of dairy science·2020
Same author

Can anticoagulation therapy in cerebral venous thrombosis associated with Behçet's disease be stopped without relapse?

Revue neurologique·2018
Same author

Effect of rubber mats and perforation in the lying area on claw and limb lesions of fattening pigs.

Animal : an international journal of animal bioscience·2018
Same author

Moderate lameness leads to marked behavioral changes in dairy cows.

Journal of dairy science·2018

Interferon alpha shows promise for treating Behçet

Area of Science:

  • Rheumatology and Immunology
  • Vasculitis Research
  • Autoimmune Disease Therapeutics

Context:

  • Behçet's disease is a rare autoimmune vasculitis with unknown etiology.
  • Current therapeutic options for Behçet's disease have limitations, especially for refractory cases.
  • Interferon alpha (IFN-α) has emerged as a potential treatment, with varying dosage regimens reported.

Purpose:

  • To review the current evidence on the efficacy of interferon alpha in managing Behçet's disease.
  • To highlight the potential benefits of interferon alpha for specific clinical manifestations.
  • To identify gaps in knowledge regarding optimal interferon alpha treatment protocols.

Summary:

  • Interferon alpha (IFN-α) demonstrates efficacy in Behçet's disease cases resistant to conventional therapies, particularly immunosuppressors.

Related Experiment Videos

  • IFN-α is effective for ocular, mucocutaneous, and articular manifestations, but data for other systemic involvements are limited.
  • Reported dosages vary significantly, indicating a need for standardization.

    • Impact:

    • Suggests interferon alpha as a promising therapeutic agent for specific Behçet's disease presentations.
    • Identifies the need for further research, including multicenter trials, to establish optimal treatment strategies.
    • Highlights the importance of defining treatment duration, relapse risks, and combination therapies for interferon alpha use.